Gland Pharma (NSE:GLAND) Interest Expense : ₹-262 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gland Pharma's interest expense for the three months ended in Mar. 2024 was ₹ -100 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-262 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gland Pharma's Operating Income for the three months ended in Mar. 2024 was ₹ 2,660 Mil. Gland Pharma's Interest Expense for the three months ended in Mar. 2024 was ₹ -100 Mil. Gland Pharma's Interest Coverage for the quarter that ended in Mar. 2024 was 26.72. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gland Pharma Interest Expense Historical Data

The historical data trend for Gland Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Interest Expense Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-62.51

-29.11

-34.02

-74.47

-262.00

Gland Pharma Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-22.03	-49.15	-60.46	-52.81	-99.58

Gland Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-262 Mil.

Gland Pharma (NSE:GLAND) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gland Pharma's Interest Expense for the three months ended in Mar. 2024 was ₹-100 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹2,660 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₹1,412 Mil.

Gland Pharma's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	2660.41	/	-99.58
	=	26.72

The higher the ratio, the stronger the company's financial strength is.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines